Company Overview of Boston Therapeutics, Inc.
Boston Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements to address blood sugar management and inflammatory diseases. It produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy post-meal blood glucose levels. The company’s lead product candidates include BTI-320, a non-systemic, carbohydrate based compound, which has completed a Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic patients; and IPOXYN, an injectable anti-necrosis drug candidate ...
1750 Elm Street
Manchester, NH 03104
Founded in 2009
Key Executives for Boston Therapeutics, Inc.
Founder, Chairman, Chief Executive Officer, Treasurer and Member of the Scientific Advisory Board
Total Annual Compensation: $100.0K
Chief Financial Officer, Principal Accounting Officer, Vice President of Strategic Planning & Investor Relations and Secretary
Total Annual Compensation: $98.4K
Compensation as of Fiscal Year 2014.
Boston Therapeutics, Inc. Key Developments
Boston Therapeutics, Inc. and Benchworks SD LLC Announce Termination of Marketing Agreement
Jul 16 15
On July 10, 2015, Boston Therapeutics, Inc. was notified by Benchworks SD LLC that Benchworks was terminating the Marketing Agreement dated as of May 14, 2014 between the company and Benchworks effective July 9, 2015. The Agreement expired by its terms on May 14, 2015 but the parties had continued to operate under the terms of the Agreement on an at will basis following the expiration. Under the terms of the Agreement, the company had granted Benchworks the exclusive right to promote, market, sell and distribute SUGARDOWN, the company's dietary product for diabetes, pre-diabetes and blood sugar management, in North America for an initial term of one year, subject to extension in accordance with the terms of the Agreement. Benchworks was responsible for and bore the expense for marketing an commercializing SUGARDOWN, including the creation and payment for marketing, creative and promotional materials. The Agreement defined certain minimum net sales levels that Benchworks must achieve to maintain exclusivity and provided for splits of net revenues from the sale of SUGARDOWN in the Territory between the company and Benchworks.
Boston Therapeutics, Inc. Presents at July 2015 Global Online CEO Conference, Jul-23-2015 03:30 PM
Jul 16 15
Boston Therapeutics, Inc. Presents at July 2015 Global Online CEO Conference, Jul-23-2015 03:30 PM. Speakers: Anthony D. Squeglia, Chief Financial Officer, Principal Accounting Officer, Vice President of Strategic Planning & Investor Relations and Secretary.
Boston Therapeutics, Inc. to Present Data on BTI-320, its Novel, Non-Systemic, Non-Hypoglycemic Drug Candidate to Manage Blood Glucose
Jun 9 15
Boston Therapeutics, Inc. will present data on BTI-320, its novel, non-systemic, non-hypoglycemic drug candidate to manage blood glucose, as a poster presentation at the 75th Annual Meeting of the American Diabetes Association being held in Boston, June 5th to the 9th. The researchers concluded that BTI-320 acts as a competitive inhibitor of enzymes, such as amylase, lactase, maltase, and sucrase among other key carbohydrate hydrolyzing enzymes BTI-320 is a non-systemic, non-hypoglycemic drug in a chewable tablet designed to be taken before meals in order to reduce post-meal rapid elevations of blood glucose in people who need to manage their blood sugar levels. BTI-320 is a proprietary drug to be taken before meals and works via the gastrointestinal tract to block the action of carbohydrate hydrolyzing enzymes. BTI-320 reduces blood glucose elevations from rapid excursions after a meal by reducing the glycemic load (the rush of absorbable glucose and fructose) from foods.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 18, 2015
March 13, 2015